PURPOSE: 18-Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) has a role in recurrent colorectal cancer. This study was designed to assess the impact of PET-CT on management of primary rectal cancer. METHODS: Eighty-three patients with rectal cancer underwent PET-CT scan between 2002 and 2005. Referring physicians prospectively recorded stage and management plan after conventional imaging before PET-CT scan, which were compared to subsequent stage and management after PET-CT. RESULTS: Staging PET-CT caused a change in stage from conventional imaging in 26 patients (31 percent). Twelve (14 percent) were upstaged (7 change in N stage; 4 change in M stage; 1 change in N and M stage), and 14 (17 percent) were downstaged (10 change in N stage; 3 change in M stage; 1 change in N and M stage). PET-CT scan altered management intent in seven patients (8 percent) (curative to palliative 6 patients; palliative to curative 1 patient). Management was altered in ten patients (12 percent). There was no difference in impact with respect to tumor height. CONCLUSIONS: PET-CT scan impacts the management of patients with primary rectal cancer and influences staging/therapy in a third of patients and should be a component of rectal cancer workup.
PURPOSE:18-Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) has a role in recurrent colorectal cancer. This study was designed to assess the impact of PET-CT on management of primary rectal cancer. METHODS: Eighty-three patients with rectal cancer underwent PET-CT scan between 2002 and 2005. Referring physicians prospectively recorded stage and management plan after conventional imaging before PET-CT scan, which were compared to subsequent stage and management after PET-CT. RESULTS: Staging PET-CT caused a change in stage from conventional imaging in 26 patients (31 percent). Twelve (14 percent) were upstaged (7 change in N stage; 4 change in M stage; 1 change in N and M stage), and 14 (17 percent) were downstaged (10 change in N stage; 3 change in M stage; 1 change in N and M stage). PET-CT scan altered management intent in seven patients (8 percent) (curative to palliative 6 patients; palliative to curative 1 patient). Management was altered in ten patients (12 percent). There was no difference in impact with respect to tumor height. CONCLUSIONS: PET-CT scan impacts the management of patients with primary rectal cancer and influences staging/therapy in a third of patients and should be a component of rectal cancer workup.
Authors: R O Perez; A Habr-Gama; G P São Julião; P B Lynn; C Sabbagh; I Proscurshim; F G Campos; J Gama-Rodrigues; S C Nahas; C A Buchpiguel Journal: Tech Coloproctol Date: 2014-02-08 Impact factor: 3.781
Authors: Pier Paolo Mainenti; Delfina Iodice; Sabrina Segreto; Giovanni Storto; Mario Magliulo; Giovanni Domenico De Palma; Marco Salvatore; Leonardo Pace Journal: World J Gastroenterol Date: 2011-03-21 Impact factor: 5.742
Authors: Mary E Charlton; Jennifer E Hrabe; Kara B Wright; Jennifer A Schlichting; Bradley D McDowell; Thorvardur R Halfdanarson; Chi Lin; Karyn B Stitzenberg; John W Cromwell Journal: J Gastrointest Surg Date: 2015-12-09 Impact factor: 3.452
Authors: Jang Eun Lee; Sang Woo Kim; Jin Su Kim; Kyu Yong Choi; Won Kyung Kang; Seong Taek Oh; Ie Ryung Yoo; Sung Hoon Kim Journal: World J Gastroenterol Date: 2012-09-28 Impact factor: 5.742